Arizona Joins $29.6 Million Multistate Settlement With Generic Drugmaker Glenmark

Queen Creek, Arizona — Arizona Attorney General Kris Mayes announced Thursday that the state has joined 47 other states and territories in a $29.6 million agreement with Glenmark, a maker of generic medications, to resolve claims that the company took part in a scheme to drive up prices and hold back competition on a range of generic prescription drugs.

Under the terms disclosed July 23, Glenmark agreed to assist the states as their broader antitrust litigation continues against the 33 companies and 25 executives still facing the states' claims, according to the attorney general's office. The company also committed to internal changes intended to keep its practices in line with competition law.

The agreement follows earlier resolutions with Lannett, Bausch, Apotex and Heritage that together totaled $66.95 million, the office said. The states' first trial in the long-running generic-drug cases is expected to take place in Hartford, Connecticut, and is anticipated to be scheduled for late 2026.

"Glenmark and generic drug manufacturers illegally conspired to inflate prices and prevent real competition," said Attorney General Mayes. "We are holding them accountable for their unlawful conduct and providing relief to Arizonans who may have been harmed by their actions."

State officials said people who purchased a generic prescription drug made by Glenmark, Lannett, Bausch, Apotex or Heritage between May 2009 and December 2019 may be eligible for compensation and can check their eligibility at aggenericdrugs.com or by calling 1-866-290-0182.

Queen Creek, a fast-growing town that spans parts of Maricopa and Pinal counties southeast of Phoenix, is among the Arizona communities whose residents may qualify for compensation if they bought covered generic medications during the affected years.